Replies to post #279791 on Avid Bioservices Inc (CDMO)

[goodJohnhunting]

goodJohn, that is incorrect. Bavituximab performed as expected. See official communications on the topic.

Then those responsible for trial design failed. And what is "performed as expected"?

As expected in relation to unreliable phase II data?? You're thought process proves that Phase II should have been redone.

If the control arm doesn't exceed then the trial wouldn't have been stopped and the stat. sig. improvement that PPHM communicated later would have been obtained in a blinded way good to file for approval.

One big pie wheel in the sky. See above..

Maybe reliable Phase II data shows 2tonelephant, and Sunrise is designed with such knowledge.

BTW, can anyone tell me what the optimal dosage of bavituximab is? Oh wait, we don't have reliable data for this knowledge.. But go ahead and spend millions on Sunrise? Total failure in thinking, IMO.

All the best,
John